לוסרטה 50 - Losarta 50

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

××× ×× ×× × ××¡×¤××

×§×××¦× ×¤×¨××§××××××ª (ATC4)

C09CA
Angiotensin II antagonists, plain

××¨××× ×¤×¢×× (ATC5)

Losartan POTASSIUM 50MG âC09CA01

×¦××¨×ª ××ª×

×¤××× - PER OS

×¦××¨×ª ××× ××

×××××, TABLETS
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

Hypertension: Losarta 50 mg is indicated for the treatment of hypertensionHeart failure: Losarta 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate.Switching patients with heart failure who are stable on an ACE inhibitor to Losarta 50 mg is not recommended.Renal protection in Type-2 diabetic patients with proteinuria: Losarta 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losarta 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.The benefit of Losarta 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

01/03/2002

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª
×××¤×× ×××××× ××©×ª× ××ª××ª ×-1 ××¨× ×××¢× ×-30 ×"×, ×¢×××¨ ×××× ×©×× ×¡××× ×××ª×¨ ×××¥ ×× ×× ×× ×¡×¤××§×ª ××, ××¡××× ×× ××¡×£ ××¨×××©××ª ××××¤×× ××ª××©××¨×× ××©××××× ×××©×¤××ª ××¢××× ACE ×× ×©×¤××ª× ×ª××¤×¢××ª ××××× ××××¤×× ×××××¨.			OLMESARTAN MEDOXOMIL VALSARTAN LOSARTAN IRBESARTAN CANDESARTAN
×××× ××¡××× ××¤×¨××××× ××¨×× ××¢× 1 ××¨×, ××©×××× ×¢× ××¢××× ACE
×××× ××¡××× ×××ª×¨ ×××¥ ×× ×× ×× ×¡×¤××§×ª ×× ××¡××× ×× ××¡×£ ××¨×××©××ª ××××¤×× ××ª××©××¨×× ××©××××× ×××©×¤××ª ××¢××× ACE ×× ×©×¤××ª× ×ª××¤×¢××ª ××××× ××××¤××

×©××××© ××¡×

××¡××¨×ª ××××× ××¡×

××ª×¨××¤× ×××××¨× ×ª×× ×ª× ×××§×¨×× ××××:

×. ×××× ××¡××× ×××ª×¨ ×××¥ ×× ×× ×× ×¡×¤××§×ª ×× ××¡××× ×× ××¡×£ ××¨×××©××ª ××××¤×× ××ª××©××¨×× ××©××××× ×××©×¤××ª ××¢××× ACE ×× ×©×¤××ª× ×ª××¤×¢××ª ××××× ××××¤×× ×××××¨;

×. ×××¤×× ×××××× ××©×ª× ××ª××ª ×-1 ××¨× ×××¢× ×-30 ×"×, ×¢×××¨ ×××× ×©×× ×¡××× ×××ª×¨ ×××¥ ×× ×× ×× ×¡×¤××§×ª ××, ××¡××× ×× ××¡×£ ××¨×××©××ª ××××¤×× ××ª××©××¨×× ××©××××× ×××©×¤××ª ××¢××× ACE ×× ×©×¤××ª× ×ª××¤×¢××ª ××××× ××××¤×× ×××××¨.

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

××× ×¢××× ××¨××¤×
Â

××××¨× ××¢××× 31.03.2020
××××¨× ××¢××× ××¦×¨×× 16.06.2014 (××¡×× Microsoft Word)

×¢××× ××¦×¨××	Â ×¢××× ××¦×¨×× ×¢××¨××ª 31.03.2020 ×¢××× ××¦×¨×× ×¢×¨×××ª - ÙØ´Ø±Ø© ÙÙÙØ³ØªÙÙÙ Ø¨Ø§ÙÙØºØ© Ø§ÙØ¹Ø±Ø¨ÙØ© 31.03.2020 ×¢××× ××¦×¨×× ×× ××××ª - Patient information leafletâ 31.03.2020

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×××¡×¨×× 50 ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	CTS CHEMICAL INDUSTRIES LTD, ISRAEL
×©× ××¢× ××¨××©××	CTS CHEMICAL INDUSTRIES LTD, ISRAEL
×¨××©×××	×ª××¨×× ×××©×: 02/2007. ×¨××©××× ××ª××¨××: 11/2013
×ª××¨×× ×¢×××× ×××¨××	14/05/19

השינוי האחרון נעשה בֹ־17 במרץ 2014 ב־07:08

לוסרטה 50 - Losarta 50

ויקיתרופות